Comparative Studies of the Effects of RS-8359 and Safrazine on Monoamine Oxidase In-vitro and In-vivo in Mouse Brain
- 1 January 1989
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 41 (1) , 32-36
- https://doi.org/10.1111/j.2042-7158.1989.tb06324.x
Abstract
The effect of RS-8359, (±)-4-(4-cyanophenyl)amino-6,7-dihydro-7-hydroxy-5H-cyclopenta[d]-pyrimidine on monoamine oxidase (MAO) has been compared with a hydrazinic MAO inhibitor, safrazine (β-piperonylisopropylhydrazine hydrochloride,) which is a MAO inhibitor used clinically. In-vitro radiochemical determination of MAO activity showed that the IC50 of RS-8359 was 0·52 μM for the deamination of 5-hydroxytryptamine (5-HT) in the mouse brain mitochondrial preparation, while β-phenylethylamine (PEA) deamination was inhibited by only 20% at 100 μM of the drug. 5-HT deamination in the brain homogenate prepared from mice killed 60 min after administration of RS-8359 was inhibited significantly by 14 and 48%, at 30 and 100 mg kg−1 (p.o.), respectively, while deamination of PEA was little affected at the same doses. On the other hand, safrazine strongly inhibited both 5-HT and PEA deaminations, but showed no selectivity toward the substrate used. The extent of MAO inhibition by RS-8359, measured fluorometrically with kynuramine as a substrate in the brain homogenate, was independent of preincubation up to 80 min. In contrast, the inhibitory potency of safrazine was strengthened by preincubation in a time-dependent manner. Oral administration of RS-8359 (3-30 mg kg−1) caused a dose-dependent increase in endogenous monoamines in mouse brain, which disappeared a few hours after its administration. Increase in monoamine content caused by safrazine lasted for at least 24 h. These results indicate that RS-8359 is a reversible and specific inhibitor of MAO-A, while safrazine is an irreversible and non-specific MAO inhibitor, in-vivo and in-vitro in mouse brain.This publication has 22 references indexed in Scilit:
- An improved fluorimetric assay for brain monoamine oxidasePublished by Elsevier ,2002
- Effects of RS-2232, a potential antidepressant, on the levels of monoamines, precursor amino acids and their related metabolites in mouse brain.The Japanese Journal of Pharmacology, 1987
- Changes of Biogenic Amines and Their Metabolites in Postmortem Brains from Patients with Alzheimer‐Type DementiaJournal of Neurochemistry, 1984
- Selective inhibitors of monoamine oxidase A and B: Biochemical, pharmacological, and clinical propertiesMedicinal Research Reviews, 1984
- Biochemical Assessment of Serotonergic and Cholinergic Dysfunction and Cerebral Atrophy in Alzheimer's DiseaseJournal of Neurochemistry, 1983
- Processes Regulating the Functional Activity of Brain 5-Hydroxytryptamine: Results of Animal Experimentation and Their Relevance to the Understanding and Treatment of DepressionPharmacopsychiatry, 1978
- The brain serotonergic system in the affective disordersProgress in Neuro-Psychopharmacology, 1978
- Another look at the monoamine oxidases and the monoamine oxidase inhibitor drugsLife Sciences, 1974
- Further studies on the inhibition of monoamine oxidase by M & B 9302 (clorgyline)—I: Substrate specificity in various mammalian speciesBiochemical Pharmacology, 1969
- A sensitive and specific assay for the estimation of monoamine oxidaseBiochemical Pharmacology, 1963